Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2005 1
2006 1
2007 1
2008 2
2009 4
2010 1
2011 5
2012 4
2013 2
2014 4
2015 1
2016 1
2017 2
2018 1
2019 2
2022 2
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Results by year

Filters applied: . Clear all
Page 1
What makes a good drug target?
Gashaw I, Ellinghaus P, Sommer A, Asadullah K. Gashaw I, et al. Among authors: ellinghaus p. Drug Discov Today. 2011 Dec;16(23-24):1037-43. doi: 10.1016/j.drudis.2011.09.007. Epub 2011 Sep 16. Drug Discov Today. 2011. PMID: 21945861 Review.
Novel aspects of fibrin(ogen) fragments during inflammation.
Jennewein C, Tran N, Paulus P, Ellinghaus P, Eble JA, Zacharowski K. Jennewein C, et al. Among authors: ellinghaus p. Mol Med. 2011 May-Jun;17(5-6):568-73. doi: 10.2119/molmed.2010.00146. Epub 2011 Jan 4. Mol Med. 2011. PMID: 21210072 Free PMC article. Review.
FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/3 mRNA Expression.
Sternberg CN, Petrylak DP, Bellmunt J, Nishiyama H, Necchi A, Gurney H, Lee JL, van der Heijden MS, Rosenbaum E, Penel N, Pang ST, Li JR, García Del Muro X, Joly F, Pápai Z, Bao W, Ellinghaus P, Lu C, Sierecki M, Coppieters S, Nakajima K, Ishida TC, Quinn DI. Sternberg CN, et al. Among authors: ellinghaus p. J Clin Oncol. 2023 Jan 20;41(3):629-639. doi: 10.1200/JCO.21.02303. Epub 2022 Oct 14. J Clin Oncol. 2023. PMID: 36240478 Free PMC article. Clinical Trial.
What makes a good drug target?
Gashaw I, Ellinghaus P, Sommer A, Asadullah K. Gashaw I, et al. Among authors: ellinghaus p. Drug Discov Today. 2012 Feb;17 Suppl:S24-30. doi: 10.1016/j.drudis.2011.12.008. Epub 2011 Dec 11. Drug Discov Today. 2012. PMID: 22155646
Rogaratinib: A potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer models.
Grünewald S, Politz O, Bender S, Héroult M, Lustig K, Thuss U, Kneip C, Kopitz C, Zopf D, Collin MP, Boemer U, Ince S, Ellinghaus P, Mumberg D, Hess-Stumpp H, Ziegelbauer K. Grünewald S, et al. Among authors: ellinghaus p. Int J Cancer. 2019 Sep 1;145(5):1346-1357. doi: 10.1002/ijc.32224. Epub 2019 Mar 13. Int J Cancer. 2019. PMID: 30807645 Free PMC article.
32 results